Esperion Therapeutics (ESPR) Interest Coverage Ratio Growth (3y) (2015 - 2026)
Esperion Therapeutics (ESPR) Interest Coverage Ratio Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 17.14% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.23% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -28.01% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -32.31% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 26.99% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 41.72% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 53.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.83% |
| Dec 31, 2025 | 48.41% |
| Sep 30, 2025 | 46.45% |
| Jun 30, 2025 | 27.94% |
| Mar 31, 2025 | 28.08% |
| Dec 31, 2024 | 64.89% |
| Sep 30, 2024 | 36.15% |
| Jun 30, 2024 | 27.33% |
| Mar 31, 2024 | 35.82% |
| Dec 31, 2023 | 35.93% |
| Sep 30, 2023 | 51.75% |
| Jun 30, 2023 | -27.89% |
| Mar 31, 2023 | 42.58% |
| Dec 31, 2022 | 40.80% |
| Sep 30, 2022 | 43.68% |
| Jun 30, 2022 | 81.21% |
| Sep 30, 2021 | -85.27% |
| Jun 30, 2021 | -58.39% |
| Mar 31, 2021 | -235.11% |
| Dec 31, 2020 | 79.32% |